Technical Analysis for CMOPF - Cosmo Pharmaceuticals N.V

Grade Last Price % Change Price Change
grade F 84.85 -17.66% -18.2000
CMOPF closed down 17.66 percent on Wednesday, February 20, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical CMOPF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing Low Bearish -17.66%
Hot IPO Pullback Bullish Swing Setup -17.66%
Narrow Range Bar Range Contraction -17.66%

Older signals for CMOPF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product that uses an amended form of the MMX technology in order to deliver butyric acid and inulin directly to the colon. The company also provides Eleview, a submucosal injectable composition for extracting polyps and adenomas; Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous lesion detection during colonoscopies; and Aemcolo, a pharmaceutical product used for the treatment of bacterial infections of the colon, such as traveler's diarrhea, infectious colitis, clostridium difficile associated disease, and diverticulitis, as well as for treatment of inflammatory bowel diseases and hepatic encephalopathy. In addition, it offers Qolotag, a medical device that enhances the detection of lesions during sigmoidoscopies; Remimazolam, an ultra-short-acting sedative/anesthetic. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Medicine RTT Medical Specialties Clinical Medicine Pharmaceutical Disease Autoimmune Diseases Ulcerative Colitis Diarrhea Inflammatory Bowel Disease Bacterial Infections Gram Positive Bacteria Inflammatory Bowel Diseases Nutraceutical Product Pharmaceutical Product
Is CMOPF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 149.0
52 Week Low 84.85
Average Volume 413
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 121.2939
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line -3.141
MACD Signal Line -0.6282
MACD Histogram -2.5128
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.8500
Resistance 3 (R3) 84.8500 84.8500 84.8500
Resistance 2 (R2) 84.8500 84.8500 84.8500 84.8500
Resistance 1 (R1) 84.8500 84.8500 84.8500 84.8500 84.8500
Pivot Point 84.8500 84.8500 84.8500 84.8500 84.8500
Support 1 (S1) 84.8500 84.8500 84.8500 84.8500 84.8500
Support 2 (S2) 84.8500 84.8500 84.8500 84.8500
Support 3 (S3) 84.8500 84.8500 84.8500
Support 4 (S4) 84.8500